Aricept (donepezil IR 10 mg) — Competitive Intelligence Brief

Aricept (donepezil IR 10 mg) (Aricept (donepezil IR 10 mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetylcholinesterase inhibitor. Area: Neurology.

phase 3 Acetylcholinesterase inhibitor Acetylcholinesterase (AChE) Neurology Small molecule

Target snapshot

Aricept (donepezil IR 10 mg) (Aricept (donepezil IR 10 mg)) — Eisai Inc.. Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aricept (donepezil IR 10 mg) TARGET	Aricept (donepezil IR 10 mg)	Eisai Inc.	phase 3	Acetylcholinesterase inhibitor	Acetylcholinesterase (AChE)
Propranolol+pyridostigmine	Propranolol+pyridostigmine	Seoul National University Hospital	marketed	Beta-blocker + Acetylcholinesterase inhibitor combination	Beta-adrenergic receptors; Acetylcholinesterase
Midodrine + pyridostigmine	Midodrine + pyridostigmine	Seoul National University Hospital	marketed	Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination	Alpha-1 adrenergic receptor; acetylcholinesterase
IV Neostigmine Methylsulfate + Atropine Sulphate	IV Neostigmine Methylsulfate + Atropine Sulphate	Damanhour Teaching Hospital	marketed	Acetylcholinesterase inhibitor + Antimuscarinic	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
Neostigmine w/ Glycopyrrolate	Neostigmine w/ Glycopyrrolate	University of Texas Southwestern Medical Center	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate)
TIVA - Neostigmine 70	TIVA - Neostigmine 70	Pontificia Universidade Catolica de Sao Paulo	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase
Neostigmine + Glycopyrrolate	Neostigmine + Glycopyrrolate	Merck Sharp & Dohme LLC	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Acetylcholinesterase inhibitor class)

1. Eisai Inc. · 2 drugs in this class
2. Ludwig-Maximilians - University of Munich · 1 drug in this class
3. Neurognostics · 1 drug in this class
4. Pontificia Universidade Catolica de Sao Paulo · 1 drug in this class
5. Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
6. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
7. Shanghai Mental Health Center · 1 drug in this class